Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Condition: Childhood Burkitt Lymphoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Choroid Plexus Tumor; Childhood Craniopharyngioma; Childhood Grade I Meningioma; Childhood Grade II Meningioma; Childhood Grade III Meningioma; Childhood High-grade Cerebral Astrocytoma; Childhood Infratentorial Ependymoma; Childhood Low-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Childhood Supratentorial Ependymoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Brain Tumor; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Unspecified Childhood Solid Tumor, Protocol Specific
MeSH terms: Burkitt Lymphoma; Lymphoma; Neoplasms; Glioma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Astrocytoma; Meningioma; Ependymoma; Medulloblastoma; Neuroectodermal Tumors; Neuroectodermal Tumors, Primitive; Lymphoma, Non-Hodgkin; Lymphomatoid Granulomatosis; Craniopharyngioma; Adamantinoma; Choroid Plexus Neoplasms; Glioblastoma; Spinal Cord Neoplasms; Recurrence
Study type: Interventional
Phase: Phase 1

Summary: 
      This phase I trial is studying the side effects and best dose of ispinesib in treating young
      patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy,
      such as ispinesib, work in different ways to stop the growth of cancer cells, either by
      killing the cells or by stopping them from dividing
    

Detailed description: 
      PRIMARY OBJECTIVES:

      I. Determine the maximum tolerated dose and recommended phase II dose of ispinesib in
      pediatric patients with refractory solid tumors or lymphoma.

      II. Define and describe the toxicities of ispinesib in these patients. III. Characterize the
      pharmacokinetics of ispinesib in these patients.

      SECONDARY OBJECTIVES:

      I. Define, preliminarily, the antitumor activity of ispinesib. II. Determine the relationship
      between CYP3A4 gene polymorphisms and pharmacokinetics in patients treated with this regimen.

      OUTLINE: This is a multicenter, dose-escalation study.

      Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28
      days for 24 courses in the absence of disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of ispinesib until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
      of 6 patients experience dose-limiting toxicity.

      Patients undergo blood and tumor sample collection periodically for pharmacokinetic and gene
      polymorphism correlative studies.

      After completion of study therapy, patients are followed for 30 days.
    

Intervention name(s): ispinesib; laboratory biomarker analysis; pharmacological study
Intervention type(s): Drug; Other; Other
Intervention description(s): Given IV; Correlative studies; Correlative studies
Other intervention name(s): CK0238273; SB-715992; pharmacological studies
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment